358 related articles for article (PubMed ID: 30465179)
1. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
[TBL] [Abstract][Full Text] [Related]
2. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
4. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
5. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
6. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
[TBL] [Abstract][Full Text] [Related]
7. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.
Jolles S; Borte M; Nelson RP; Rojavin M; Bexon M; Lawo JP; Wasserman RL
Clin Immunol; 2014 Feb; 150(2):161-9. PubMed ID: 24412910
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
13. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
15. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
16. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
[TBL] [Abstract][Full Text] [Related]
17. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.
Nicolay U; Haag S; Eichmann F; Herget S; Spruck D; Gardulf A
Qual Life Res; 2005 Sep; 14(7):1683-91. PubMed ID: 16119180
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home.
Al-Saud B; AlRumayyan N; Alfattani A; Awwad SA; Al Saud D; Mohammed R; Albuhairi S; Elshorbagi S; Balhareth SS; Al-Dhekri H; Arnaout R; De Vol EB; Al-Mousa H
J Clin Immunol; 2023 Aug; 43(6):1360-1366. PubMed ID: 37145392
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.
Patel NC; Torgerson T; Thakar MS; Younger MEM; Sriaroon P; Pozos TC; Buckley RH; Morris D; Vilkama D; Heimall J
J Clin Immunol; 2023 Oct; 43(7):1557-1565. PubMed ID: 37266769
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]